Quick answers
- What is Doxorubicin Hydrochloride Liposome?
- Doxorubicin Hydrochloride Liposome is a brand name of Doxorubicin hydrochloride, a prescription medicine. The FDA NDC Directory lists 3 Doxorubicin Hydrochloride Liposome products in 1 strength and form.
- Who makes Doxorubicin Hydrochloride Liposome?
- Baxter Hlthcare Corp holds the FDA application for Doxorubicin Hydrochloride Liposome (NDA050718, approved November 17, 1995). 1 other company (repackagers or distributors) also list Doxorubicin Hydrochloride Liposome products.
- Is there a generic or store brand of Doxorubicin Hydrochloride Liposome?
- Yes. The FDA NDC Directory lists 17 other products with the same active ingredients, strength and form as a Doxorubicin Hydrochloride Liposome product, 13 of them generic. Ask your pharmacist whether one is right for you.
- Has Doxorubicin Hydrochloride Liposome been recalled?
- No recall linked to Doxorubicin Hydrochloride Liposome products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Doxorubicin Hydrochloride Liposome is
Each Doxorubicin Hydrochloride Liposome product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Doxorubicin hydrochloride · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| doxorubicin hydrochloride 2 mg/mL injection, suspension, liposomal (intravenous) | Doxorubicin Hydrochloride Liposome | 17 products, 8 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Doxorubicin hydrochloride →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA050718 | Baxter Hlthcare Corp | November 17, 1995 | 2 |
| ANDA219881 | Qilu Pharm Hainan | February 3, 2026 | 1 |
Companies that list Doxorubicin Hydrochloride Liposome
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Doxorubicin Hydrochloride Liposome products.
- Baxter Healthcare Company2 products
- Sagent Pharmaceuticals1 product
Recalls
No recall linked to Doxorubicin Hydrochloride Liposome products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.